Furin sustains tumor-promoting signals in KRAS- and BRAF-mutated colorectal cancer by engaging the TGF-β1-COX-2 axis in a reciprocal regulatory network

Yiyang Liu G. Siegfried S. Pernot Zongsheng He Marta Martin Bornez S. Tejpar Fanny Castanet G. Désolneux Serge Evrard Torsten Steinmetzer John W. M. Creemers A. Khatib

Jul 2026 · Oncogene · Vol 45, pp. 3479 - 3496 · 0 citations · 69 references

Medicine

TL;DR

Cutting Furin activity slowed tumor growth, improved the response to common chemotherapy drugs, reduced blood vessel formation, and increased the presence of cancer-killing immune cells are found.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Aug 2026

CAF-derived TGF-β1 activates an LBH-mediated β-catenin stabilization program to drive gastric cancer progression

It is shown that the transcriptional cofactor LBH drives mutation-independent Wnt activation and malignant progression in GC via a tumour microenvironment-regulated post-translational stabilization mechanism, elucidate a critical tumour–stroma crosstalk mechanism and establish the targeted disruption of the LBH–β-caten...

Zhi-Xiong Su, Guifeng Zhang, J. Zhong et al. · Cell Death & Disease · 0 citations

Aug 2026

RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling.

Findings reveal a mechanism by which RASA2-dependent epigenetic and transcriptional reprogramming promotes metastatic progression and nominate the RASA2- TGFβ2-GLI1 axis as a potential therapeutic target in PDAC.

Taochen He, Qiang-Da Chen, Yan-Fei An et al. · Cancer Research · 0 citations

Open access Aug 2026

Targeting the ANKRD54/ELOVL6 axis suppresses malignancy in BRAF mutant colorectal cancer by disrupting fatty acid metabolism and promoting ferroptosis

BRAF-mutant (BRAF-MT) colorectal cancer (CRC) represents a clinically aggressive subtype characterized by distinct biological features and significantly worse prognosis compared to BRAF wild-type (BRAF-WT) CRC, with median survival reduced by approximately 40%. The therapeutic resistance of BRAF-MT CRC stems prim...

Yichao Hou, Di Wu, Yanyu Wei et al. · Journal of Experimental &amp... · 0 citations

Jul 2026

Targeting JOSD2 degrades β-catenin to suppress colorectal cancer metastasis by disrupting RAS/ERK/β-catenin axis.

Findings identify JOSD2 as a critical oncogenic factor that promotes β-catenin activity and validate JOSD2 as an underlying therapeutic target for metastatic CRC (mCRC) both in vitro and in vivo.

Yue Liu, Shuyu Yang, Wen-Han Zhang et al. · Acta Pharmacologica Sinica · 0 citations

Open access Aug 2026

FOXD3 Is Functionally Linked to NF-κB Signaling in KRAS G12C-Mutant NSCLC Cells

Findings support a functional association between FOXD3 overexpression and reduced NF-κB-related transcriptional activity in KRAS G12C-mutant NSCLC models, although the present data do not establish direct causal mediation by NF-κB.

Peng Xu, Jie Peng, Chao Guo et al. · Cells · 0 citations

Open access Aug 2026

WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer.

Functional assays demonstrated that WNT activation enhances tumor progression in immunocompetent settings, indicating immune evasion as a key driver of malignant progression.

M. Mastel, A. Guiseris Martinez, Umberto Pozza et al. · Gastroenterology · 0 citations